risk
factor
weigh
heavili
decis
admit
patient
suspect
communityacquir
pneumonia
cap
includ
advanc
age
comorbid
condit
physic
examin
laboratori
chest
radiograph
find
support
diagnosi
strength
recommend
c
firstlin
antibiot
therapi
acut
bacteri
rhinosinus
includ
amoxicillin
trimethoprimsulfamethoxazol
tmpsmx
day
strength
recommend
highdos
amoxicillin
mgkg
divid
twice
daili
day
antibiot
choic
initi
treatment
acut
otiti
media
aom
strength
recommend
b
lack
subject
improv
hour
treatment
amoxicillin
indic
treatment
failur
point
patient
switch
amoxicillin
clavulan
patient
persist
symptom
therapi
highdos
amoxicillinclavulan
receiv
dose
intramuscular
ceftriaxon
strength
recommend
b
pharmacotherapi
treatment
influenza
initi
within
hour
start
symptom
shown
reduc
durat
symptom
day
compar
placebo
strength
recommend
b
american
associ
studi
liver
diseas
recommend
person
high
risk
infect
recipi
transfus
organ
transplant
juli
hcv
screen
becam
standard
healthcar
worker
needlestick
injuri
sexual
partner
hcvinfect
person
test
hcv
infect
strength
recommend
c
current
patient
hiv
infect
requir
use
antiretrovir
medic
advers
effect
risk
develop
resist
associ
treatment
medic
initi
count
fall
cellsml
set
acut
infect
strength
recommend
b
sever
immun
compromis
occur
hivposit
patient
count
level
less
cellsml
point
prophylact
antibiot
tmpsmx
recommend
strength
recommend
b
case
travel
diarrhea
eg
enterotoxigen
e
coli
shigella
salmonella
campylobact
infect
prompt
treatment
fluoroquinolon
children
tmpsmx
shown
reduc
durat
ill
day
less
day
strength
recommend
patient
fever
bloodi
diarrhea
treat
empir
tmpsmz
fluoroquinolon
strength
recommend
recommend
treatment
regimen
gonococc
urethr
proctiti
includ
ceftriaxon
cefixim
ciprofloxacin
ofloxacin
levofloxacin
singl
dose
chlamydi
infect
rule
suspicion
high
azithromycin
doxycyclin
given
concomitantli
strength
recommend
parenter
administr
penicillin
g
prefer
drug
treatment
stage
syphili
strength
recommend
infecti
diseas
lead
caus
morbid
mortal
men
part
world
given
broad
scope
infecti
diseas
affect
men
select
sever
topic
especi
relev
patient
popul
topic
includ
communityacquir
pneumonia
cap
sinus
otiti
media
externa
influenza
viral
hepat
b
c
human
immunodefici
viru
hiv
infect
infecti
diarrhea
sexual
transmit
diseas
aim
chapter
provid
exhaust
review
topic
primarili
present
uptod
evidencebas
approach
diagnosi
treatment
common
ill
primari
care
physician
care
male
patient
epidemiologypathogenesi
cap
seriou
ill
affect
million
peopl
unit
state
annual
result
hospit
approxim
case
mortal
rate
diseas
sixth
common
caus
death
unit
state
empir
antibiot
therapi
necessari
sinc
etiolog
organ
identifi
well
case
complic
treatment
cap
emerg
antibiot
resist
streptococcu
pneumonia
perhap
common
organ
implic
rate
pneumonia
higher
men
discharg
hospit
men
versu
women
microaspir
organ
common
mechan
infect
lead
cap
though
hematogen
spread
also
occur
host
factor
predispos
patient
increas
risk
develop
cap
includ
smoke
underli
lung
diseas
eg
chronic
obstruct
pulmonari
diseas
copd
bronchiectasi
uremia
malnutrit
alcohol
abus
ciliari
motil
defect
eg
kartagen
syndrom
alter
conscious
immunosuppress
eg
hivacquir
immunodefici
syndrom
aid
corticosteroid
use
advanc
age
gastric
acid
suppress
bacteri
viral
virul
factor
play
signific
role
develop
cap
microorgan
implic
caus
agent
cap
common
typic
bacteri
etiolog
includ
pneumonia
haemophilu
influenza
staphylococcu
aureu
moraxella
catarrhali
group
streptococcu
variou
anaerob
gramneg
bacteria
common
atyp
bacteria
includ
legionella
speci
mycoplasma
pneumonia
chlamydia
pneumonia
although
influenza
common
caus
viral
cap
adenoviru
parainfluenza
viru
pneumonia
also
occur
respiratori
syncyti
viru
signific
pathogen
infant
newli
emerg
strain
corona
viru
led
epidem
outbreak
sever
acut
respiratori
syndrom
china
canada
tabl
highlight
common
caus
cap
three
set
ambulatori
care
hospit
nonintens
care
unit
icu
icu
pneumonia
suspect
patient
present
cough
product
sputum
dyspnea
especi
fever
present
elderli
patient
pneumonia
may
fever
respiratori
symptom
frequent
present
failur
thrive
confus
patient
tachypnea
abnorm
pulmonari
examin
result
exhibit
rhonchi
abnorm
breath
sound
tactil
fremitu
egophoni
often
aid
diagnosi
american
thorac
societi
guidelin
state
initi
diagnost
evalu
patient
suspect
cap
includ
chest
radiograph
sputum
gram
stain
cultur
chest
radiograph
use
determin
extent
unilobar
versu
multilobar
charact
interstiti
infiltr
versu
consolid
pneumonia
sputum
studi
guid
specif
therapi
controversi
regard
use
gram
stain
cultur
poor
sensit
specif
group
still
consid
test
use
target
initi
therapi
guidelin
recommend
use
sputum
gram
stain
cultur
presenc
drugresist
bacteria
organ
cover
empir
therapi
suspect
puls
oximetri
complet
blood
count
platelet
differenti
serum
electrolyt
hepat
enzym
measur
renal
function
test
may
help
prognost
tool
help
identifi
patient
requir
hospit
admit
patient
sever
ill
chronic
lung
diseas
arteri
blood
ga
perform
assess
oxygen
hypercapnia
hospit
patient
two
set
blood
cultur
drawn
patient
pleural
effus
undergo
thoracentesi
assess
empyema
complic
parapneumon
effus
serolog
antibodi
test
cold
agglutinin
assay
help
initi
perform
patient
condit
improv
epidemiolog
purpos
although
clinic
predict
rule
use
decid
whether
patient
cap
admit
hospit
observ
treatment
rule
supplant
clinic
judgment
gener
follow
risk
factor
weigh
heavili
decis
admit
age
older
year
complic
patient
cap
respond
adequ
antibiot
therapi
within
day
initi
treatment
decreas
fever
improv
clinic
statu
eg
decreas
dyspnea
normal
blood
pressur
decreas
white
blood
cell
count
patient
condit
fail
improv
worsen
therapi
workup
complic
pneumonia
initi
pulmonari
complic
pneumonia
includ
lung
abscess
parapneumon
effus
empyema
although
find
chest
radiograph
remain
abnorm
week
longer
diagnosi
cap
repeat
imag
via
either
computer
tomographi
scan
chest
followup
chest
radiograph
may
help
patient
whose
condit
fail
improv
worsen
time
complic
particularli
result
pneumonia
bacteremia
includ
mening
endocard
pericard
acut
respiratori
distress
syndrom
may
also
occur
sever
ill
may
necessit
intub
purifi
capsular
polysaccharid
pneumococc
vaccin
offer
protect
invas
strain
bacteria
caus
cap
patient
risk
factor
place
greatli
elev
risk
develop
cap
strongli
encourag
receiv
pneumococc
vaccin
tabl
singl
vaccin
given
patient
age
year
older
includ
receiv
vaccin
year
turn
year
old
repeat
vaccin
indic
year
immunocompromis
patient
yearli
influenza
vaccin
administ
concomitantli
patient
risk
factor
approxim
million
case
acut
bacteri
sinus
annual
unit
state
result
common
cold
influenzalik
ill
occur
averag
two
three
time
per
year
adult
estim
acut
respiratori
ill
result
sinus
viral
bacteri
fungal
caus
acut
sinus
implic
tabl
healthcar
cost
relat
diagnosi
manag
sinus
estim
close
billion
annual
common
predispos
condit
associ
bacteri
sinus
viral
infect
result
thicken
sinu
mucosa
subsequ
obstruct
ostia
result
accumul
secret
allow
bacteri
colon
normal
steril
sinu
mucosa
maxillari
sinu
commonli
involv
follow
ethmoid
sphenoid
frontal
sinus
risk
factor
includ
swim
eg
microaspir
contamin
water
allergi
nasal
obstruct
eg
polyp
tumor
decreas
mucociliari
activ
eg
cystic
fibrosi
smoke
granulomat
diseas
eg
wegen
granulomatosi
immunosuppress
eg
hivaid
chronic
corticosteroid
use
dental
infect
upper
teeth
particularli
second
bicuspid
first
second
molar
respons
case
maxillari
sinus
environment
factor
includ
high
altitud
air
pollut
live
midwest
southern
unit
state
increas
risk
acut
bacteri
sinus
femal
seem
higher
risk
male
overal
elderli
person
increas
risk
develop
sinus
symptom
acut
sinus
particularli
maxillari
sinus
includ
congest
purul
nasal
discharg
facial
pain
maxillari
tooth
discomfort
less
week
often
report
facial
pain
exacerb
bend
forward
less
specif
symptom
includ
headach
fever
fatigu
halitosi
may
also
occur
high
fever
acut
facial
pain
periorbit
edema
diplopia
chang
mental
statu
warrant
immedi
evalu
potenti
neurolog
complic
acut
sinus
diagnosi
acut
bacteri
sinus
imprecis
although
case
like
viral
rhinosinus
primari
care
physician
prescrib
antibiot
case
center
diseas
control
prevent
endors
antibiot
treatment
acut
sinus
patient
persist
nasal
discharg
longer
day
maxillari
sinu
pain
facial
tooth
tender
sinu
radiographi
recommend
uncompl
acut
sinus
thought
inaccur
sinu
transillumin
limit
valu
diagnost
tool
distinguish
bacteri
viral
sinus
sinu
aspir
use
routin
evalu
uncompl
acut
sinus
invas
expens
computer
tomographi
scan
sinus
limit
refractori
chronic
case
sinus
modal
accur
distinguish
bacteri
viral
caus
symptom
acut
sinus
resolv
within
week
without
antibiot
therapi
case
antibiot
case
recent
guidelin
sinu
allergi
health
partnership
recommend
treatment
acut
bacteri
sinus
patient
symptom
sinus
improv
day
whose
condit
worsen
day
firstlin
antibiot
therapi
acut
bacteri
rhinosinus
includ
amoxicillin
trimethoprimsulfamethoxazol
tmpsmx
day
agent
prove
superior
placebo
effect
agent
expens
greater
risk
advers
effect
reserv
seriou
infect
requir
treatment
amoxicillinclavulan
cefuroxim
cefpodoxim
partial
incomplet
resolut
symptom
initi
cours
antibiot
durat
initi
therapi
extend
complet
cours
day
patient
moder
diseas
minim
improv
initi
therapi
highdos
amoxicillinclavulan
levofloxacin
use
area
unit
state
high
level
penicillinresist
pneumonia
resist
macrolid
tmpsmx
also
preval
secondgener
cephalosporin
eg
cefuroxim
use
initi
therapi
recent
highdos
shortcours
regimen
day
use
improv
adher
decreas
drug
exposur
clinic
outcom
use
regimen
compar
favor
tradit
regimen
complic
acut
sinus
includ
orbit
cellul
common
pott
puffi
tumor
cellul
frontal
sinu
intracrani
abscess
mening
cavern
sinu
thrombosi
complic
often
requir
surgic
drainag
intraven
antibiot
nasal
cultur
specimen
obtain
guid
therapi
complic
refractori
case
initi
treatment
broadspectrum
antibiot
includ
ceftriaxon
without
aminoglycosid
given
intraven
often
warrant
cultur
prove
posit
acut
sinus
precursor
chronic
sinus
addit
aerob
bacteria
fungi
anaerob
bacteria
play
signific
role
chronic
sinus
acut
otiti
media
aom
predominantli
diseas
infant
children
highest
incid
occur
age
month
less
commonli
seen
adult
cost
treat
aom
unit
state
estim
billion
recent
accur
estim
childhood
boy
affect
frequent
girl
aom
character
middl
ear
effus
demonstr
via
pneumat
otoscopi
tympanometri
air
fluid
level
bulg
tympan
membran
evid
acut
inflamm
opaqu
white
yellow
erythemat
tympan
membran
purul
effus
symptom
otalgia
irrit
fever
otiti
media
effus
present
similar
fashion
purul
collect
fluid
behind
tympan
membran
visual
unless
drainag
extern
auditori
canal
exist
microbiolog
diagnosi
usual
feasibl
rare
necessari
common
organ
caus
aom
includ
pneumonia
h
influenza
catarrhali
patient
improv
subject
symptom
especi
fever
hour
observ
consid
antibiot
treatment
although
univers
held
mani
physician
still
overtreat
aom
antibiot
expert
opinion
state
antibiot
therapi
defer
mani
asymptomat
patient
case
otiti
media
effus
children
younger
year
age
recurr
bout
aom
like
appropri
treat
antibiot
therapi
highdos
amoxicillin
mgkg
divid
twice
daili
day
antibiot
choic
initi
treatment
aom
lack
subject
improv
hour
treatment
amoxicillin
suggest
treatment
failur
patient
switch
amoxicillinclavulan
patient
persist
symptom
administr
highdos
amoxicillinclavulan
receiv
dose
intramuscular
ceftriaxon
case
suspect
resist
organ
macrolid
eg
azithromycin
tmpsmx
cephalexin
cefaclor
loracarbef
cefdinir
also
use
multipl
cours
broadspectrum
antibiot
avoid
routin
prophylact
therapi
recommend
recurr
aom
complic
aom
includ
hear
loss
chronic
otiti
media
tympan
membran
perfor
mastoid
rare
complic
includ
brain
epiduralsubdur
abscess
mening
later
sinu
cavern
vein
thrombosi
otiti
externa
oe
infect
extern
auditori
canal
primarili
affect
children
uncommon
among
adult
particularli
person
diabet
immunocompromis
patient
popul
develop
oe
point
lifetim
risk
factor
includ
excess
clean
ear
canal
via
cotton
swab
aggress
itch
ear
canal
swim
swimmer
ear
increas
humid
wear
ear
canal
devic
hear
aid
headphon
dive
cap
skin
condit
includ
psoriasi
eczema
seborrh
dermat
acn
increas
risk
oe
ear
involv
patient
oe
typic
present
otalgia
otorrhea
pain
commonli
exacerb
pull
ear
lobe
sometim
chew
auditori
canal
occlud
fluid
discharg
patient
may
complain
full
hear
loss
fever
system
sign
uncommon
uncompl
case
oe
physic
examin
serou
purul
exud
commonli
seen
auditori
canal
pull
pinna
elicit
pain
mastoid
tender
crepitu
suggest
complic
infect
case
mastoid
strongli
consid
referr
otolaryngologist
promptli
facilit
erythemat
tympan
membran
indic
concomit
otiti
media
common
organ
caus
oe
includ
pseudomona
aeruginosa
aureu
fungal
organ
aspergillu
speci
recov
case
one
third
case
polymicrobi
includ
anaerob
bacteroid
fragili
peptostreptococcu
speci
cleans
involv
auditori
canal
room
temperatur
tap
water
attempt
optim
topic
therapi
perform
low
suction
direct
visual
altern
cotton
swab
use
gentli
mop
secret
canal
flush
extern
auditori
canal
attempt
unless
intact
tympan
membran
visual
tympan
membran
perfor
flush
may
caus
signific
cochlear
damag
therapi
treatment
oe
list
tabl
topic
antibiot
treatment
choic
uncompl
oe
recommend
drop
given
day
symptom
resolv
patient
requir
total
day
treatment
addit
steroid
ear
drop
solut
may
help
decreas
canal
inflamm
quickli
canal
edema
sever
wick
place
canal
may
requir
drop
appli
frequent
time
daili
canal
open
system
antibiot
rare
need
use
oe
persist
concomit
om
present
complic
oe
includ
necrot
oe
focal
furuncl
mastoid
chronic
oe
lead
hear
loss
necrot
oe
lifethreaten
extens
oe
mastoid
tempor
bone
common
etiolog
agent
p
aeruginosa
treatment
often
requir
parenter
antibiot
period
surgeri
otolaryngologist
consult
earli
necrot
oe
suspect
highest
risk
includ
elderli
person
particularli
diabet
immunocompromis
patient
eg
hivaid
human
epidem
influenza
caus
type
b
influenza
virus
influenza
virus
also
caus
pandem
name
hemagglutinin
h
neuraminidas
n
surfac
antigen
influenza
b
virus
categor
subtyp
caus
pandem
sinc
influenza
influenza
influenza
b
virus
circul
worldwid
last
centuri
three
pandem
influenza
occur
devast
pandem
outbreak
spanish
flu
kill
million
peopl
worldwid
unit
state
outbreak
avian
influenza
southeast
asia
start
caus
death
januari
rais
concern
seemingli
overdu
pandem
epidemiolog
averag
approxim
peopl
die
influenzarel
complic
admit
hospit
influenza
year
unit
state
young
children
year
elderli
person
older
year
compos
major
case
mortal
rate
person
older
year
age
year
influenza
complic
also
much
common
men
highrisk
condit
includ
copd
coronari
heart
diseas
diabet
mellitu
immunodefici
eg
hivaid
chronic
corticosteroid
use
eg
mgday
hematolog
cancer
eg
leukemia
chronic
renal
failur
male
may
disproportion
affect
influenza
risk
contractur
higher
rate
mani
highrisk
condit
influenza
spread
via
persontoperson
contact
epidem
unvaccin
suscept
person
get
infect
develop
symptom
incub
period
day
averag
day
viral
shed
occur
day
start
symptom
continu
averag
day
thereaft
immunocompromis
patient
shed
influenza
viru
period
week
uncompl
influenza
present
abrupt
onset
fever
chill
headach
myalgia
nonproduct
cough
sore
throat
rhiniti
influenza
season
particularli
epidem
occur
specif
clinic
symptom
high
influenza
usual
resolv
within
day
cough
malais
may
persist
sever
week
complic
influenza
adult
adolesc
includ
primari
viral
pneumonia
secondari
bacteri
pneumonia
eg
aureu
bacteri
sepsi
myositi
myocard
pericard
enceph
transvers
myeliti
death
result
either
viral
bacteri
pneumonia
influenza
season
diagnosi
diseas
made
basi
clinic
suspicion
sensit
specif
influenzalik
ill
fever
myalgia
malais
nonproduct
cough
rhiniti
headach
approxim
respect
avail
diagnost
test
influenza
includ
viral
cultur
viral
serolog
assay
rapid
antigen
test
polymeras
chain
reaction
pcr
immunofluoresc
assay
rapid
influenza
test
requir
nasopharyng
swab
sensit
specif
use
start
influenza
season
confirm
epidem
posit
predict
valu
noninfluenza
season
influenza
suspect
neg
predict
valu
test
differenti
influenza
b
identifi
specif
influenza
subtyp
eg
versu
diagnost
test
clinic
valu
time
best
way
prevent
influenza
complic
vaccin
vaccin
healthi
adult
older
year
age
prevent
influenza
vaccin
person
significantli
decreas
work
absente
use
healthcar
resourc
among
person
older
year
vaccin
effect
prevent
influenzarel
hospit
effect
prevent
influenzarel
death
costbenefit
analysi
estim
averag
annual
save
vaccin
unfortun
vaccin
rate
vari
depend
risk
categori
healthcar
worker
vaccin
rate
gener
mani
peopl
refus
influenza
vaccin
claim
given
flu
know
someon
gotten
flu
vaccin
percept
persist
regardless
much
evid
contrari
healthcar
worker
often
busi
get
vaccin
despit
ampl
opportun
educ
two
influenza
vaccin
current
endors
us
food
drug
administr
fda
inactiv
kill
viru
influenza
vaccin
commonli
use
given
intramuscular
inject
live
attenu
influenza
vaccin
administ
intranas
spray
vaccin
equal
effect
protect
influenza
b
grown
egg
albumin
administ
yearli
live
vaccin
expens
inactiv
vaccin
approv
use
children
younger
year
old
sinc
live
viru
administ
immunosuppress
patient
site
reaction
fever
occur
inactiv
vaccin
wherea
advers
affect
associ
live
formul
current
advisori
committe
immun
practic
recommend
vaccin
influenza
summar
tabl
antivir
medic
use
either
treatment
chemoprophylaxi
influenza
b
tabl
current
four
licens
drug
two
class
amantadin
rimantadin
activ
influenza
fda
approv
treatment
prophylaxi
adult
advers
effect
includ
central
nervou
system
cn
toxic
eg
anxieti
dizzi
insomnia
difficulti
concentr
gastrointestin
toxic
eg
nausea
vomit
symptom
usual
mild
resolv
drug
discontinu
sever
advers
effect
includ
delirium
seizur
hallucin
rare
seen
high
serum
level
medic
neuraminidas
inhibitor
oseltamivir
tamiflu
zanamivir
relenza
fda
approv
treatment
adult
influenza
b
oseltamivir
approv
chemoprophylaxi
frequent
advers
effect
oseltamivir
includ
nausea
vomit
zanamivir
administ
aerosol
inhal
addit
nausea
vomit
patient
experienc
wheez
declin
pulmonari
function
pharmacotherapi
treatment
influenza
initi
within
hour
start
symptom
shown
reduc
durat
symptom
day
compar
placebo
addit
decreas
durat
symptom
oseltamivir
zanamivir
shown
decreas
hospit
use
antibiot
chemoprophylaxi
use
prevent
influenza
certain
highrisk
popul
see
tabl
unfortun
use
antivir
agent
treatment
chemoprophylaxi
led
resist
especi
amantadin
rimantadin
hepat
hepat
one
common
vaccineprevent
diseas
unit
state
caus
picornaviru
produc
symptomat
asymptomat
diseas
hepat
viru
hav
infect
often
acquir
fecalor
spread
either
persontoperson
transmiss
ingest
contamin
food
water
sourc
children
often
get
asymptomat
diseas
thu
play
import
role
transmiss
diseas
among
famili
member
day
care
center
staff
frequent
report
sourc
infect
household
member
sexual
partner
although
infect
hepat
histori
one
exposur
identifi
sourc
casefat
rate
hepat
unit
state
higher
among
adult
older
year
age
chronic
liver
diseas
group
higher
risk
hepat
diseas
includ
intern
travel
men
sex
men
msm
intraven
drug
user
day
care
staff
work
infect
primat
patient
clottingfactor
disord
also
consid
high
risk
clot
factor
transfus
healthcar
worker
food
handler
higher
risk
diseas
may
sourc
transmiss
hepat
averag
incub
period
day
rang
day
symptom
includ
fever
malais
nausea
abdomin
pain
jaundic
scleral
icteru
dark
urin
last
gener
less
month
person
may
prolong
relaps
syndrom
last
month
chronic
infect
hepat
treatment
support
infect
selflimit
diagnosi
hav
infect
base
combin
symptom
presenc
serum
transaminas
ie
alanin
aminotransferas
aspart
aminotransferas
bilirubin
elev
definit
diagnosi
requir
serolog
evid
acut
diseas
via
presenc
immunoglobulin
igm
antihav
presenc
igg
antihav
suffici
diagnos
acut
hepat
approxim
us
popul
exposur
time
prevent
hav
infect
achiev
vaccin
passiv
immun
inactiv
wholeviru
hav
vaccin
use
unit
state
confer
protect
adult
two
formul
use
unit
state
includ
havrix
vaqta
advers
event
vaccin
rare
usual
limit
local
irrit
site
intramuscular
inject
twinrix
combin
vaccin
contain
hav
hepat
b
compon
administ
three
dose
month
complet
seroprotect
gener
occur
week
first
dose
receiv
second
dose
provid
longterm
protect
year
intern
travel
msm
person
use
intraven
intranas
illicit
drug
person
clottingfactor
disord
person
occup
risk
person
chronic
liver
diseas
strongli
encourag
receiv
hav
vaccin
immunoglobulin
ig
provid
protect
hav
infect
passiv
transfer
antibodi
pool
human
plasma
ig
administ
intramuscularli
dose
mlkg
provid
month
seroprotect
hepat
ig
administ
prophylact
unvaccin
expos
highrisk
person
administ
simultan
hav
vaccin
elig
person
includ
close
contact
person
confirm
case
staff
child
care
center
hav
infect
outbreak
occur
person
expos
food
prepar
havinfect
food
handler
travel
go
highrisk
area
receiv
hav
vaccin
less
week
travel
hepat
b
viru
hbv
dna
viru
replic
primarili
liver
like
hav
vaccineprevent
diseas
howev
unlik
hav
chronic
diseas
state
occur
hepat
b
eventu
lead
endstag
liver
diseas
hbv
primarili
transmit
percutan
mucos
exposur
infecti
blood
bodi
fluid
contain
hbv
person
high
risk
becom
infect
hbv
includ
intraven
intranas
drug
user
person
engag
unprotect
sex
multipl
partner
infant
born
infect
women
healthcar
worker
recommend
vaccin
infant
adolesc
hbv
result
plummet
incid
diseas
unit
statesfrom
popul
popul
preval
hbv
infect
unit
state
current
approxim
million
person
chronic
carrier
viru
incid
infect
men
twice
women
versu
incub
period
hbv
day
rang
day
exposur
jaundic
clinic
symptom
acut
diseas
includ
anorexia
malais
nausea
vomit
jaundic
fatal
rate
highest
among
person
older
year
age
asymptomat
diseas
also
occur
common
children
younger
year
approxim
acut
infect
adult
becom
chronic
persist
carrier
ie
hepat
b
surfac
antigen
hbsag
posit
person
develop
chronic
activ
hepat
chronic
hbv
carrier
increas
risk
hepatocellular
carcinoma
cirrhosi
membran
glomerulonephr
polyarter
nodosum
chronic
serum
sicknesslik
syndrom
diagnosi
acut
hbv
infect
base
clinic
symptom
serolog
marker
particularli
hbsag
patient
eventu
develop
hepat
b
surfac
antibodi
hbsab
clear
infect
success
vaccin
hbsag
clear
month
patient
consid
chronic
carrier
presenc
hepat
b
core
igg
antibodi
hbcab
adequ
confirm
clear
hbv
protect
diseas
sequela
thu
person
hbcab
posit
hbsab
neg
hbsag
neg
consid
immun
hbv
infect
person
hbeag
posit
consid
highli
infect
like
transmit
viru
other
unprotect
sex
accident
needl
stick
recent
pcr
test
use
quantifi
hbv
dna
guid
treatment
chronic
diseas
immunocompromis
patient
eg
person
hiv
aid
less
like
clear
viru
blood
specif
therapi
exist
treatment
acut
hbv
infect
howev
sever
antivir
drug
includ
lamivudin
emtricitabin
emtriva
adefovir
hepsera
tenofovir
viread
entecavir
baraclud
alphainterferon
cellferon
use
chronic
infect
patient
decreas
hbv
viral
load
entecavir
alphainterferon
lamivudin
adefovir
approv
fda
treatment
hbv
prevent
hbv
infect
best
achiev
vaccin
howev
hepat
b
immunoglobulin
hbig
also
use
postexposur
prophylaxi
hbsag
antigen
use
vaccin
produc
unit
state
use
recombin
dna
technolog
vaccin
avail
singleantigen
formula
recombivax
hb
engerixb
combin
hav
vaccin
twinrix
sinc
march
hbv
vaccin
contain
thimeros
formul
safe
minor
site
reaction
common
advers
effect
vaccin
consist
three
intramuscular
inject
month
adult
children
immunocompet
adult
vaccin
like
protect
year
hbv
vaccin
current
recommend
childhood
mandat
mani
state
children
allow
enter
school
immunocompromis
patient
eg
person
hivaid
patient
receiv
dialysi
person
receiv
clot
factor
via
transfus
healthcar
worker
person
come
contact
blood
workplac
injectionintranas
drug
user
person
multipl
sex
partner
inmat
worker
correct
facil
intern
travel
strongli
consid
prophylact
vaccin
postexposur
prophylaxi
involv
give
hbig
hbv
vaccin
hbig
prepar
plasma
donor
high
concentr
antihb
postexposur
prophylaxi
offer
person
experi
percutan
permucos
exposur
hbv
unvaccin
person
receiv
hepat
b
vaccin
hbig
mlkg
im
dose
person
vaccin
known
respond
postexposur
prophylaxi
requir
person
vaccin
respons
statu
unknown
serum
antibodi
test
perform
patient
adequ
respons
iuml
requir
postexposur
prophylaxi
wherea
inadequ
respons
receiv
hbig
hepat
b
vaccin
hepat
c
viru
hcv
singlestrand
rna
viru
caus
chronic
liver
diseas
common
reason
liver
transplant
unit
state
preval
hcv
antibodi
antihcv
unit
state
approxim
new
infect
occur
everi
year
thu
million
person
antihcv
posit
die
year
endstag
liver
diseas
highest
incid
infect
among
year
old
male
african
american
like
develop
chronic
infect
hcv
transmit
contact
infect
blood
mucos
secret
increas
risk
acquir
hcv
infect
includ
intraven
intranas
drug
user
healthcar
worker
person
unprotect
sex
multipl
partner
person
undergo
bodi
pierc
tattoo
data
acquisit
viru
sexual
contact
tattoo
inconsist
acquir
hcv
infect
blood
suppli
blood
product
unlik
today
unit
state
given
current
blood
blood
product
test
sexual
transmiss
hcv
reportedli
lower
hbv
especi
among
monogam
coupl
transmiss
casual
contact
believ
occur
perinat
transmiss
occur
infant
born
antihcvposit
mother
quit
alarm
newli
diagnos
case
risk
factor
identifi
previou
month
unlik
hav
hbv
acut
infect
hcv
usual
asymptomat
jaundic
present
fewer
case
eighti
percent
person
acut
infect
hcv
remain
antihcv
posit
persist
elev
serum
transaminas
level
patient
chronic
hcv
infect
asymptomat
clue
diseas
elev
serum
transaminas
level
cirrhosi
eventu
develop
patient
chronic
infect
averag
year
immunocompromis
patient
eg
person
hivaid
alcohol
may
progress
cirrhosi
quickli
develop
cirrhosi
silent
endstag
liver
diseas
eventu
occur
rate
per
year
patient
eventu
develop
jaundic
ascit
anasarca
esophag
varic
mortal
rate
month
unless
liver
transplant
perform
hepatocellular
carcinoma
develop
rate
per
year
patient
cirrhosi
diagnosi
hcv
infect
difficult
person
present
symptomat
acut
diseas
mani
clinician
discov
infect
investig
incident
elev
serum
transaminas
level
given
success
newer
treatment
hcv
infect
earli
diagnosi
essenti
current
american
associ
studi
liver
diseas
recommend
person
high
risk
infect
see
recipi
transfus
organ
transplant
juli
hcv
screen
becam
standard
healthcar
worker
needlestick
injuri
sexual
partner
hcvinfect
person
test
person
found
hcv
posit
counsel
avoid
share
dental
shave
equip
other
cover
bleed
wound
avoid
donat
blood
blood
product
addit
hcvinfect
person
counsel
risk
sexual
transmiss
low
infect
reason
chang
sexual
practic
longterm
relationship
diagnosi
hcv
infect
achiev
via
serolog
assay
antihcv
person
posit
antihcv
undergo
hcv
pcr
test
quantifi
viral
load
genotyp
test
determin
hcv
type
eg
type
select
patient
undergo
liver
biopsi
determin
extent
hepat
diseas
treatment
decis
individu
base
sever
liver
diseas
potenti
seriou
advers
effect
likelihood
treatment
respons
presenc
comorbid
condit
thu
hcvinfect
person
monitor
expert
infecti
diseas
hepatolog
current
treatment
choic
pegyl
interferon
plu
ribavirin
period
month
success
therapi
depend
hcv
genotyp
genotyp
refractori
treatment
underli
comorbid
extent
hepat
injuri
sustain
viral
respons
defin
absenc
hcv
viru
blood
month
treatment
achiev
treat
person
retreat
sometim
necessari
nonrespond
case
relaps
human
immunodefici
viru
acquir
immunodefici
syndrom
hiv
human
retroviru
infect
destroy
cell
lymphocyt
time
lead
sever
immunodefici
allow
develop
opportunist
infect
neoplasm
hiv
transmit
person
person
sexual
intercours
mother
child
via
child
birth
breast
milk
infect
blood
product
includ
needlestick
injuri
sinc
approxim
million
death
attribut
hivaid
worldwid
forti
million
peopl
estim
live
hiv
infect
global
million
peopl
becom
newli
infect
million
death
yearli
unit
state
million
peopl
current
live
hiv
infect
peopl
aid
estim
aidsrel
death
unit
state
earli
msm
constitut
major
new
infect
recent
women
account
new
infect
unit
state
heterosexu
transmiss
rate
continu
rise
despit
effort
prevent
focus
condom
use
hiv
infect
remain
signific
public
health
concern
global
unit
state
death
attribut
aid
occur
men
mani
peopl
infect
hiv
unawar
statu
sinc
often
symptom
associ
chronic
infect
therefor
perform
hiv
antibodi
screen
test
patient
highrisk
exposur
critic
import
health
patient
prevent
hiv
transmiss
other
convers
patient
acut
infect
hiv
constel
symptom
consist
fever
rash
myalgia
headach
anorexia
also
may
develop
laboratori
abnorm
includ
thrombocytopenia
transamin
unfortun
sign
symptom
quit
nonspecif
may
confus
viral
infect
therefor
high
index
suspicion
must
maintain
hiv
test
must
perform
risk
factor
discov
care
evalu
tabl
identifi
patient
acut
hiv
infect
import
sinc
peopl
highli
infecti
other
time
initi
infect
sinc
viru
multipli
high
rate
organ
immun
respons
remain
unclear
whether
initi
antiretrovir
therapi
time
clinic
benefit
although
issu
remain
subject
ongo
studi
sinc
decreas
rate
hiv
replic
earli
cours
infect
may
theoret
preserv
specif
cell
respons
standard
method
screen
hiv
infect
hiv
enzymelink
immunosorb
assay
elisa
test
screen
antibodi
react
antigen
although
test
high
sensit
specif
falseposit
result
occasion
occur
nonspecif
crossreact
antibodi
present
therefor
confirmatori
test
via
western
blot
essenti
diagnosi
test
detect
specif
host
antibodi
respons
certain
epitop
western
blot
analysi
result
interpret
posit
least
two
three
band
present
falseposit
elisa
result
encount
often
one
three
band
present
band
present
correspond
known
antigen
screen
elisa
test
result
may
neg
first
week
acut
hiv
infect
window
period
sinc
antihiv
antibodi
requir
time
develop
acut
infect
hiv
often
replic
high
level
diagnosi
made
perform
either
quantit
pcr
assay
hiv
rna
viral
load
qualit
provir
hiv
dna
pcr
assay
confirmatori
test
repeat
elisa
later
time
remain
mandatori
enorm
amount
research
effort
direct
toward
develop
effect
therapeut
strategi
hiv
infect
past
year
sinc
multipl
antiretrovir
medic
becam
avail
act
differ
stage
viral
life
cycl
longterm
prognosi
patient
live
hiv
infect
improv
dramat
pharmacotherapi
avail
four
differ
class
act
disrupt
viral
replic
level
hiv
rna
dna
transcript
nucleosid
revers
transcriptas
inhibitor
nonnucleosid
revers
transcriptas
inhibitor
hiv
capsid
assembl
proteas
inhibitor
hiv
fusion
posit
cell
fusion
inhibitor
drug
use
certain
combin
guidanc
hiv
specialist
creat
highli
activ
antiretrovir
therapi
fulli
suppress
hiv
replic
allow
regener
cell
reconstitut
patient
immun
system
improv
level
function
immun
system
success
reconstitut
patient
longer
high
risk
opportunist
infect
associ
morbid
mortal
occur
aid
current
patient
hiv
infect
requir
use
antiretrovir
medic
advers
effect
risk
develop
resist
associ
treatment
medic
initi
count
fall
cellsml
set
acut
infect
morbid
mortal
associ
hiv
infect
due
consequ
immun
suppress
ie
aid
sometim
seriou
advers
effect
antiretrovir
medic
viral
replic
left
unmonitor
patient
diagnos
earli
cours
hiv
infect
patient
develop
resist
antiretrovir
medic
count
inexor
declin
time
case
end
result
loss
appropri
function
immun
system
allow
develop
opportunist
infect
neoplasm
tabl
differ
opportunist
infect
may
observ
variou
level
immun
suppress
depend
count
level
rel
normal
count
cellsml
greater
patient
hiv
infect
encount
greater
risk
bacteri
infect
includ
pneumonia
soft
tissu
infect
reactiv
herp
viru
infect
herp
simplex
viru
hsv
varicella
zoster
may
also
occur
rang
patient
becom
high
risk
kaposi
sarcoma
tuberculosi
count
fall
cellsml
sever
immun
compromis
occur
count
level
less
cellsml
point
prophylact
antibiot
tmpsmx
recommend
patient
rang
risk
pneumocysti
jerovici
formerli
pneumocysti
carinii
pneumonia
cryptococcosi
toxoplasmosi
reactiv
patient
consid
profoundli
immun
compromis
count
drop
cellsml
point
risk
sever
infect
includ
dissemin
mycobacterium
avium
complex
cytomegaloviru
reactiv
lymphoma
past
year
hiv
specialist
learn
although
antiretrovir
medic
dramat
alter
natur
histori
hiv
aid
also
carri
risk
advers
effect
drug
interact
individu
medic
class
medic
uniqu
set
potenti
advers
effect
irrevers
exampl
proteas
inhibitor
nucleosid
revers
transcriptas
inhibitor
link
develop
fat
redistribut
syndrom
peripher
lipodystrophi
glucos
intoler
hyperlipidemia
occur
use
proteas
inhibitor
well
includ
lopinavirritonavir
kaletra
mitochondri
toxic
lead
lactic
acidosi
caus
nucleosid
revers
transcriptas
inhibitor
particularli
link
use
stavudin
zerit
didanosin
videx
especi
use
togeth
nonnucleosid
revers
transcriptas
inhibitor
nevirapin
viramun
caus
druginduc
hepat
sometim
sever
cutan
drug
erupt
although
antiretrovir
therapi
significantli
reduc
morbid
mortal
associ
hiv
infect
great
benefit
mani
patient
drug
must
use
judici
minim
risk
sever
toxic
effect
vaccin
develop
key
elimin
threat
spread
hiv
prevent
effort
educ
patient
import
condom
use
prevent
spread
sexual
transmit
diseas
hiv
paramount
import
intraven
drug
user
minim
risk
needleexchang
program
case
occup
exposur
eg
needlestick
injuri
sexual
assault
postexposur
prophylaxi
antiretrovir
drug
significantli
reduc
risk
infect
lastli
import
physician
work
close
local
health
depart
sexual
partner
hivinfect
patient
notifi
test
chain
ongo
risk
hiv
transmiss
other
broken
unit
state
nearli
million
episod
diarrheal
ill
occur
year
averag
one
diarrheal
episod
per
person
per
year
foodborn
diarrhea
account
one
fifth
case
million
caus
death
per
year
although
highest
mortal
worldwid
occur
among
children
unit
state
die
diarrheal
diseas
elderli
sinc
mani
differ
microorgan
caus
infecti
diarrhea
use
divid
three
group
communityacquir
travel
diarrhea
nosocomi
diarrhea
persist
diarrhea
diarrhea
last
greater
day
tabl
common
communityacquir
organ
includ
virus
noroviru
enteroviru
rotaviru
bacteria
includ
campylobact
salmonella
speci
nontyphi
shigella
speci
escherichia
coli
enterotoxigen
aureu
new
vaccin
avail
rotaviru
administ
children
month
age
previou
version
vaccin
taken
market
sever
year
ago
result
numer
fatal
case
intussuscept
travel
diarrhea
like
caus
e
coli
entamoeba
histolytica
salmonella
typhi
must
also
includ
nosocomi
diarrhea
almost
exclus
caus
clostridium
difficil
although
aureu
implic
case
diarrhea
associ
antibiot
use
although
clindamycin
classic
associ
c
difficil
infect
antibiot
particularli
broadspectrum
antibiot
caus
diseas
persist
diarrhea
commonli
caus
protozo
organ
includ
giardia
lamblia
cryptosporidium
cyclospora
isospora
belli
popul
increas
risk
develop
infecti
diarrhea
includ
young
children
immunocompromis
patient
patient
take
antibiot
hivposit
patient
particular
risk
acquir
protozo
diarrheal
infect
entamoeba
histolytica
cryptosporidium
low
gastric
ph
children
younger
year
place
significantli
increas
risk
salmonella
infect
thorough
histori
first
step
determin
sourc
infecti
diarrhea
patient
recent
travel
oversea
within
week
e
coli
entamoeba
typhi
consid
endem
foodassoci
diarrhea
caus
organ
includ
campylobact
aureu
salmonella
typhimurium
shigella
listeria
norovirus
see
tabl
season
diarrhea
might
implic
enterovirus
rotaviru
diarrhea
occur
consumpt
untreat
water
suggest
giardia
e
coli
infect
complet
exposur
histori
particularli
critic
foodassoci
diarrhea
public
health
implic
document
infect
report
respect
counti
epidemiolog
surveil
time
charact
diarrhea
often
help
establish
etiolog
rapid
onset
within
hour
characterist
toxinmedi
diarrhea
aureu
bacillu
cereu
somewhat
longer
period
exposur
onset
symptom
hour
commonli
seen
clostridium
perfringen
toxinmedi
diarrhea
salmonella
shigella
campylobact
gener
incub
period
hour
chronic
diarrhea
last
week
typic
cryptosporidium
giardia
infect
bloodi
diarrhea
fever
tenesmu
refer
dysenteri
indic
invas
process
although
present
characterist
entamoeba
shigella
sometim
seen
campylobact
salmonella
profus
secretori
diarrhea
ie
rice
water
diarrhea
lead
rapidli
fatal
dehydr
caus
vibrio
cholera
diarrhea
associ
upper
gastrointestin
sign
bloat
belch
typic
g
lamblia
diarrhea
fever
high
white
blood
cell
count
hospit
patient
rais
concern
c
difficil
infect
bloodi
diarrhea
without
fever
associ
renal
failur
hemolyt
urem
syndrom
suggest
enterohemorrhag
e
coli
ehec
infect
select
fecal
test
use
follow
situat
communityacquir
travel
diarrhea
especi
accompani
fever
bloodi
stool
nosocomi
diarrhea
occur
day
hospit
persist
diarrhea
last
longer
week
fecal
leukocyt
test
may
help
identifi
inflammatori
diarrhea
neither
specif
sensit
stool
cultur
assess
ova
parasit
use
investig
communityacquir
travel
diarrhea
infecti
diarrhea
selflimit
test
use
epidemiolog
studi
patient
present
bloodi
diarrhea
fever
patient
hospit
day
stool
cultur
communityacquir
organ
eg
campylobact
aureu
typhimurium
shigella
listeria
ova
parasit
unlik
help
perform
patient
howev
test
c
difficil
toxin
patient
continu
diarrhea
identifi
pathogen
colonoscopi
may
help
identifi
noninfecti
caus
diarrhea
inflammatori
bowel
diseas
treatment
dehydr
cornerston
therapi
communityacquir
infecti
diarrhea
infect
selflimit
oral
hydrat
electrolyt
solut
eg
pedialyt
world
health
organ
rehydr
solut
prefer
patient
sustain
oral
rehydr
parenter
hydrat
may
necessari
although
travel
diarrhea
usual
selflimit
tmpsmz
fluoroquinolon
reduc
durat
ill
day
day
patient
fever
bloodi
diarrhea
treat
empir
tmpsmz
fluoroquinolon
patient
like
invas
diseas
shigella
campylobact
speci
antimotil
agent
use
uncompl
travel
diarrhea
avoid
patient
fever
bloodi
diarrhea
fecal
leukocyt
treatment
ehec
antimicrobi
agent
associ
increas
risk
hemolyt
urem
syndrom
therefor
consid
care
tabl
detail
variou
treatment
regimen
infecti
diarrhea
commensur
pathogen
devast
complic
infecti
diarrhea
toxic
megacolon
bowel
perfor
suspect
patient
sudden
increas
pain
decreas
bowel
sound
septic
appear
rebound
pain
guard
palpat
abdomen
characterist
find
prompt
immedi
surgic
evalu
invas
organ
like
caus
complic
includ
entamoeba
shigella
c
difficil
c
perfringen
enteropathogen
e
coli
infect
enterohemorrhag
e
coli
infect
associ
hemolyt
urem
syndrom
children
rare
occur
adult
entamoeba
infect
lead
amoeb
liver
abscess
requir
addit
antibiot
treatment
sometim
drainag
dehydr
lead
caus
death
develop
countri
infecti
diarrhea
particularli
via
v
cholera
bacteremia
occur
typhimurium
immunocompromis
patient
eg
person
hivaid
urethr
urethr
defin
presenc
urethr
inflamm
clinic
character
discharg
mucopurul
purul
materi
dysuria
urethr
pruritu
classic
bacteri
pathogen
acut
urethr
neisseria
gonorrhoea
urethr
infect
caus
refer
collect
nongonococc
urethr
ngu
organ
clearli
associ
ngu
chlamydia
trachomati
case
pathogen
respons
chlamydianeg
ngu
includ
ureaplasma
urealyticum
trichomona
vaginali
mycoplasma
genitalium
hsv
etiolog
case
nonchlamydi
ngu
unknown
urethr
document
basi
follow
sign
mucopurul
purul
discharg
gram
stain
urethr
secret
demonstr
white
blood
cell
per
high
power
field
microscop
examin
demonstr
white
blood
cell
per
high
power
field
posit
leukocyt
esteras
test
firstvoid
urin
gram
stain
highli
sensit
specif
test
evalu
urethr
presenc
absenc
gonococc
infect
gonococc
infect
establish
document
presenc
white
blood
cell
contain
intracellular
gramneg
diplococci
rate
gonorrhea
infect
male
unit
state
common
african
american
men
age
year
histor
report
rate
gonococc
infect
men
higher
women
differ
attribut
higher
incid
asymptomat
diseas
women
occurr
infect
among
msm
incid
gonococc
infect
increas
latter
popul
gonorrhea
msm
associ
approxim
threefold
increas
risk
acquisit
hiv
infect
acut
urethr
predomin
manifest
gonorrhea
men
incub
period
typic
day
recent
studi
suggest
may
increas
dysuria
usual
promin
discharg
gener
profus
purul
ngu
epididym
proctiti
pharyng
less
common
complic
n
gonorrhoea
infect
anorect
gonorrhea
frequent
site
infect
msm
uncommon
heterosexu
men
symptom
proctiti
includ
mucopurul
rectal
discharg
anal
pruritu
tenesmu
pain
rectal
bleed
oropharyng
infect
n
gonorrhoea
frequent
asymptomat
firstlin
treatment
gonococc
pharyng
infect
either
intramuscular
ceftriaxon
oral
ciprofloxacin
dissemin
gonococc
infect
result
gonococc
bacteremia
often
highlight
petechi
pustular
acral
skin
lesion
asymmetr
arthralgia
tenosynov
septic
arthriti
rel
common
caus
infect
arthriti
young
adult
gonococc
bacteremia
often
intermitt
minimum
three
blood
cultur
obtain
dissemin
diseas
suspect
approxim
one
half
patient
dissemin
gonococc
infect
posit
cultur
blood
synovi
fluid
hospit
recommend
initi
therapi
especi
patient
may
compli
treatment
patient
examin
clinic
evid
endocard
mening
recommend
regimen
dissemin
gonococc
infect
intramuscular
intraven
ceftriaxon
g
everi
hour
cultur
n
gonorrhoea
remain
gold
standard
diagnosi
urethr
rectal
pharyng
specimen
obtain
use
cotton
swab
plate
thayermartin
agar
nucleic
acid
amplif
test
offer
noninvas
rapid
result
urin
urethr
specimen
commonli
use
assay
practic
today
sensit
specif
nucleic
acid
amplif
test
via
specimen
similar
studi
greater
via
standard
cultur
recommend
treatment
regimen
gonococc
urethr
proctiti
includ
ceftriaxon
cefixim
ciprofloxacin
ofloxacin
levofloxacin
singl
dose
tabl
quinoloneresist
n
gonorrhoea
common
hawaii
california
part
asia
pacif
among
msm
thu
quinolon
longer
recommend
treatment
gonorrhea
area
msm
firstlin
therapi
group
ceftriaxon
detail
travel
histori
patient
partner
recommend
therapi
chosen
chlamydi
infect
rule
suspicion
high
azithromycin
doxycyclin
given
concomitantli
preval
c
trachomati
differ
age
group
lower
preval
seen
among
older
men
number
case
due
pathogen
appear
decreas
case
ngu
sexual
acquir
incub
period
ngu
variabl
typic
day
exposur
patient
ngu
less
acut
onset
gonorrhea
symptom
increas
sever
day
patient
typic
present
mucoid
wateri
discharg
mani
men
infect
c
trachomati
n
gonorrhoea
asymptomat
diagnosi
chlamydi
urethr
best
made
nucleic
acid
amplif
test
use
pcr
treatment
ngu
azithromycin
doxycyclin
see
tabl
c
trachomati
also
caus
proctiti
epididym
prostat
reactiv
arthriti
reiter
syndrom
asymptomat
chlamydi
infect
associ
infertil
men
chlamydi
proctiti
defin
inflamm
distal
rectal
mucosa
rel
uncommon
occur
almost
exclus
msm
acut
epididym
commonli
caus
n
gonorrhoea
c
trachomati
among
sexual
activ
men
younger
year
old
symptom
includ
unilater
testicular
pain
tender
hydrocel
palpabl
swell
epididymi
treatment
acut
epididym
caus
n
gonorrhoea
c
trachomati
ceftriaxon
mg
intramuscular
singl
dose
plu
doxycyclin
mg
oral
twice
daili
day
patient
instruct
return
evalu
symptom
persist
recur
complet
therapi
patient
instruct
abstain
sexual
intercours
day
therapi
initi
patient
refer
evalu
treatment
sex
partner
within
preced
day
sexual
partner
often
asymptomat
unless
treat
reinfect
index
patient
spread
infect
partner
patient
persist
recurr
urethr
retreat
initi
regimen
compli
treatment
regimen
reexpos
untreat
sex
partner
persist
gonococci
isol
test
antibiot
suscept
persist
urethr
may
also
caus
organ
includ
u
urealyticum
vaginali
syphili
spirochet
diseas
caus
treponema
pallidum
often
acquir
sexual
incid
primari
secondari
syphili
increas
increas
observ
among
men
rate
primari
secondari
syphili
among
male
rose
natur
histori
syphili
divid
sever
stage
sometim
overlap
primari
syphili
incub
period
day
usual
week
painless
papul
appear
site
inocul
usual
extern
genitalia
anal
area
lip
oral
caviti
breast
finger
lesion
ulcer
within
day
produc
classic
painless
chancr
usual
resolv
week
secondari
syphili
week
month
later
major
untreat
patient
develop
symptom
sign
secondari
syphili
includ
diffus
lymphadenopathi
focal
alopecia
mucos
lesion
condyloma
lata
classic
rash
character
symmetr
red
papular
erupt
involv
entir
trunk
extrem
includ
palm
sole
becom
squamou
characterist
find
secondari
syphili
occur
approxim
patient
nonspecif
symptom
includ
fever
headach
malais
anorexia
sore
throat
myalgia
weight
loss
latent
syphili
untreat
clinic
manifest
secondari
syphili
last
week
latent
syphili
start
resolut
secondari
syphili
defin
posit
serolog
test
result
asymptomat
patient
infect
less
year
defin
earli
latent
infecti
year
late
latent
noninfecti
tertiari
syphili
variabl
level
latenc
tertiari
syphili
develop
one
third
untreat
patient
present
gummat
ie
nodul
found
anywher
bodi
often
skin
bone
cardiovascular
neurosyphili
manifest
neurolog
involv
occur
stage
syphili
acut
asymptomat
symptomat
mening
seen
primari
secondari
syphili
fear
manifest
cn
involv
occur
tertiari
syphili
includ
meningovascular
syphili
lead
cerebrovascular
accid
parenchymat
syphili
gener
paresi
tabe
dorsali
diagnosi
syphili
made
microscopi
serolog
test
darkfield
examin
direct
fluoresc
antibodi
test
lesion
exud
tissu
definit
method
diagnos
earli
syphili
serolog
test
syphili
classifi
nontreponem
treponem
assay
nontreponem
test
includ
vener
diseas
research
laboratori
vdrl
rapid
plasma
reagin
test
treponem
test
includ
fluoresc
treponem
antibodi
absorb
pallidum
particl
agglutin
test
use
one
type
serolog
test
insuffici
diagnosi
falseposit
nontreponem
test
result
may
occur
result
variou
medic
condit
eg
autoimmun
diseas
nontreponem
test
recommend
screen
tool
treponem
test
requir
confirm
nontreponem
test
usual
correl
diseas
activ
usual
becom
nonreact
time
provid
falseneg
result
sole
test
perform
patient
previou
infect
reactiv
treponem
test
usual
remain
reactiv
regardless
treatment
diseas
activ
hivinfect
patient
atyp
serolog
test
result
unusu
high
unusu
low
fluctuat
titer
posit
cerebrospin
fluid
csf
vdrl
result
diagnost
neurosyphili
specimen
contamin
blood
csf
leukocytosi
increas
csf
protein
level
common
case
neurosyphili
parenter
administr
penicillin
g
prefer
drug
treatment
stage
syphili
prepar
use
eg
benzathin
aqueou
procain
aqueou
crystallin
dosag
length
treatment
depend
stage
clinic
manifest
diseas
see
tabl
chancroid
sexual
transmit
diseas
caus
bacteria
haemophilu
ducreyi
rare
unit
state
steadi
declin
case
high
case
men
commonli
infect
women
case
occur
person
age
year
older
h
ducreyi
highli
infecti
colonyform
unit
lead
diseas
expos
person
difficult
grow
diseas
may
underestim
chancroid
present
pain
genit
papul
day
incub
papul
becom
ulcer
erythemat
base
clear
undermin
border
lesion
commonli
occur
prepuc
corona
glan
peni
one
half
infect
men
progress
develop
pain
inguin
lymphaden
diagnosi
chancroid
challeng
depend
clinic
present
neg
result
test
hsv
gram
stain
reveal
small
gramneg
rod
chain
cultur
h
ducreyi
difficult
beyond
capabl
lab
unit
state
treatment
success
case
drug
choic
includ
azithromycin
ceftriaxon
see
tabl
fluctuant
inguin
bubo
sever
lymphaden
drain
needl
aspir
may
develop
drain
fistula
sex
partner
treat
regardless
sign
symptom
sexual
contact
infect
person
within
day
symptom
present
c
trachomati
infect
also
lead
lymphogranuloma
venereum
diseas
common
tropic
subtrop
area
repres
less
genit
ulcer
unit
state
common
among
msm
clinic
character
painless
genit
ulcer
initi
heal
follow
week
painless
inguin
lymphadenopathi
untreat
lymphogranuloma
venereum
progress
inguin
bubo
chronic
fistul
tract
diagnosi
often
challeng
base
high
degre
clinic
suspicion
posit
igg
test
chlamydia
antibiot
treatment
lymphogranuloma
venereum
outlin
tabl
human
papilloma
viru
hpv
dna
viru
caus
penil
perirect
wart
men
preval
anal
hpv
ie
pcr
posit
msm
approxim
common
genotyp
seen
highrisk
type
associ
anal
cancer
nineteen
percent
men
attend
sexual
transmit
diseas
clinic
unit
state
found
seroposit
consist
risk
factor
hpv
acquisit
unprotect
sexual
activ
directli
relat
number
sexual
partner
patient
men
hpv
commonli
present
painless
cauliflowerlik
anogenit
wart
ie
condyloma
acuminatum
grow
time
although
diagnosi
hpv
often
made
clinic
basi
definit
diagnosi
obtain
via
biopsi
current
antivir
medic
avail
hpv
erad
howev
abl
treatment
use
see
tabl
hpv
transmit
even
lesion
present
condom
use
guarante
protect
viru
often
transmit
nonpenetr
sexual
contact
male
practic
anal
recept
intercours
yearli
examin
anal
wart
lesion
present
biopsi
perform
evalu
anal
cancer
vaccin
mani
serotyp
hpv
gardasil
shown
success
variou
trial
approv
fda
current
indic
femal
age
year
herp
simplex
viru
type
link
genit
infect
estim
million
person
unit
state
current
genit
hsv
although
respons
case
genit
infect
preval
rise
especi
among
women
highest
rate
seropreval
unit
state
report
among
femal
prostitut
homosexu
male
male
one
half
like
femal
infect
wide
spectrum
hsv
genit
diseas
rang
asymptomat
shed
pain
genit
ulcer
dysuria
pain
inguin
adenopathi
fever
men
vesicular
penil
ulcer
erythemat
base
dysuria
common
present
symptom
recurr
genit
lesion
common
especi
nineteen
day
averag
durat
lesion
seen
primari
infect
decreas
day
recurr
although
transmiss
sexual
partner
higher
activ
lesion
transmiss
attribut
asymptomat
viral
shed
transmiss
greater
male
versu
femal
sourc
patient
versu
diagnosi
usual
suggest
pain
shallow
genit
ulcer
viral
cultur
direct
fluoresc
antibodi
test
pcr
use
confirmatori
test
pcr
especi
use
diagnosi
asymptomat
carriag
serolog
help
epidemiolog
studi
use
acut
diagnos
infect
variou
treatment
option
hsv
genit
infect
outlin
tabl
provid
evidencebas
summari
sever
import
infect
men
exhaust
rendit
infect
found
associ
refer
educ
regard
minim
communic
transmiss
infecti
diseas
well
earli
test
treatment
remain
standard
movement
toward
minim
morbid
mortal
